Lantheus Medical Imaging has received approval from the U.S. Food and Drug Administration for version of its Definity ultrasound contrast agent that uses radiofrequency ID (RFID) technology to control the activation of the agent.
VialmixRFID for Definity uses an RFID-based activation device that is made specifically for Definity, an ultrasound contrast agent indicated for patients with suboptimal echocardiograms. The RFID technology controls the activation rate and time of Definity.
The RFID technology ensures reproducible activation of Definity, reducing the risks related to operator or medication errors, according to the company.
